Hi Uboy,The timing of the shift in sentiment towards RNA...

Hi Uboy,
The timing of the shift in sentiment towards RNA therapeutics coincides with the positive efficacy and safety profile of ATL1102 in DMD. The Report titled And a Door Opens Wide makes the point that ATL1102 was before its time. There is a growing sense that now is its time. The setbacks that are occurring in the gene therapy sector reinforce the positivity of the data around ATL1102 as well as the understanding of its mechanism of action.

Simply put, RNA therapeutics is a safer alternative to gene therapy particularly with its versatility in that it can both increase and decrease gene expression. How will this play out in the boardrooms of Big Pharma? With that in mind we need to step back and look at the size of the inflammation market and the dire need for new anti-inflammatory drugs particularly drugs that will form a backbone around which combination therapies can be built.